Interpretation of key points in the instructions for Elotuzumab

As an immunotherapy drug, Elotuzumab exerts anti-tumor effects by targeting the SLAMF7 receptor, especially in the treatment of multiple myeloma. The drug's combination regimen provides patients with multiple treatment options, but also comes with a certain risk of side effects. Therefore, during use, patients should maintain close communication with their doctors and regularly evaluate efficacy and adverse reactions to ensure the safety and effectiveness of treatment.

1. Indications

Evolizumab is indicated for the following patient groups:

Combined treatment with lenalidomide and dexamethasone: suitable for adult patients with multiple myeloma who have received 1-3 previous treatments.

Combined treatment with pomalidomide and dexamethasone: Indicated for adult patients with multiple myeloma who have received at least two therapies, including lenalidomide and a proteasome inhibitor.

2. Recommended dosage

The dose of evolizumab depends on the choice of combination drug. Specific recommended dosages are as follows:

In combination with lenalidomide and dexamethasone: 10 mg/kg intravenously every week for the first two cycles (28 days per cycle) and then every two weeks until disease progression or unacceptable toxicity.

In combination with pomalidomide and dexamethasone: 10 mg/kg intravenously every week for the first two cycles (28 days per cycle), followed by 20 mg/kg every four weeks until disease progression or unacceptable toxicity.

In addition, drugs such as dexamethasone, diphenhydramine, ranitidine, and acetaminophen should be used before treatment to reduce allergic reactions and other adverse reactions caused by drugs.

3. Adverse reactions

Common adverse reactions of evolizumab include:

When combined with lenalidomide and dexamethasone: fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, etc.;

When combined with pomalidomide and dexamethasone: constipation, hyperglycemia, etc.;

These adverse reactions are common in clinical practice, so patients' signs and symptoms need to be closely monitored to ensure timely adjustment of treatment plans to mitigate side effects.

4. Pharmacological effects

Evolizumab is an immunostimulatory antibody directed againstSLAMF7 (Signaling Lymphocyte Activation Molecule Family Member 7). SLAMF7 is a protein expressed primarily on myeloma cells and is also expressed on immune cells such as natural killer (NK) cells and plasma cells.

Mechanism of action: Evolizumab enhances its killing effect by directly activating natural killer cells (NK cells). Especially when used in combination with other drugs, it can significantly enhance the anti-tumor activity of the immune system. Evolizumab can interact with SLAMF7 on myeloma cells and further activate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby effectively killing myeloma cells.

Combination treatment effect: Non-clinical models show that evolizumab and lenalidomide, when used in combination, can activate natural killer cells and improve anti-tumor efficacy more effectively than either drug alone. In addition, evolizumab combined with pomalidomide has also demonstrated its ability to enhance antitumor effects in in vitro and in vivo experiments.

5. Storage conditions

Evolizumab should be stored within a temperature range of 2°C to 8°C (36°F to 46°F) out of direct sunlight. Medications should be kept in their original packaging until use to ensure their stability. Medications should not be frozen or shaken as this may affect their effectiveness and safety.

Reference materials:https://www.empliciti.com/